Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans

Metabolism: Clinical and Experimental

Volumn 51, Issue 10, 2002, Pages 1223-1229

  Edwards, Iris J ^a   Terry, James G ^a   Bell Farrow, Audrey D ^a   Cefalu, William T ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FRUCTOSAMINE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROTEOGLYCAN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL CIRCULATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING ASSAY; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFECT; DRUG POTENTIATION; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LIPID INTERACTION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

EID: 0036798040     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.35177     Document Type: Article

References (46)

1. De Man FHAF, Castro Cabezas M, Van Barlingen HHJJ, et al: Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: Post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 26:89-108, 1996
2. Stamler J, Vaccaro O, Neaton JD, et al: Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
3. Resengren A, Welin L, Tsipogianni A, et al: Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men: A general population study. BMJ 288:1127-1131, 1989
4. Hoff HF, Bradley WA, Heideman CL, et al: Characterization of low density lipoprotein like-particle in the human aorta from grossly normal and atherosclerotic regions. Biochim Biophys Acta 573:361-374, 1979
5. Hoff HF, Gaubatz JW: Isolation, purification, and characterization of a lipoprotein containing apo B from the human aorta. Atherosclerosis 41:273-299, 1982
6. Smith EB, Keen GA, Grant A: Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. I. Relation between fibrin and immobilization of apo B-containing lipoprotein. Atherosclerosis 84:165-171, 1990
7. Bocan TM, Schifani TA, Guyton JR: Ultrastructure of the human aortic fibrolipid lesion. Formation of the atherosclerotic lipid-rich core. Am J Pathol 123:413-424, 1986
8. Srinivasan SR, Dolan P, Radhakrishnamurtrhy B, et al: Isolation of lipoprotein-acid mucopolysaccharide complexes from fatty streaks of human aortas. Atherosclerosis 16:95-104, 1972
9. Hollander W, Paddock J, Colombo M: Lipoproteins in human atherosclerotic vessels. 1. Biochemical properties of arterial low density lipoproteins, very low density lipoproteins and high density lipoproteins. Exp Mol Pathol 30:144-171, 1979
10. Mawhinney TP, Augustyn JM, Fritz KE: Glycosaminoglycan-lipoprotein complexes from aortas of hypercholesterolemic rabbits. Part 1. Isolation and characterization. Atherosclerosis 31:155-167, 1978
11. Galis ZS, Alavi M, Moore S: Colocalization of aortic apolipoprotein B and chondroitin sulfate in an injury model of atherosclerosis. Am J Pathol 142:1432-1438, 1993
12. Nievelstein PFEM, Fogelman AM, Mottino G, et al: Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein: a deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb 11:1795-1805, 1991
13. Camejo G, Waich S, Quintero G, et al: The affinity of low density lipoproteins for an arterial macromolecular complex: A comparative study in acute coronary disease patients and controls. Atherosclerosis 24:341-354, 1976
14. Linden T, Bondjers G, Camejo G, et al: Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest 19:38-44, 1989
15. Hurt-Camejo E, Olsson U, Wiklund O, et al: Cellular consequences of the association of ApoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 17:1011-1017, 1997
16. Edwards IJ, Wagner JD, Litwak KN, et al: Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans. Diabetes Res Clin Pract 46:9-18, 1999
17. Cefalu WT, Bell-Farrow AD, Petty M, et al: Clinical validation of a new, 2nd generation fructosamine assay. Clin Chem 37:1252-1256, 1991
18. Cefalu WT, Wagner JD, Bell-Farrow AD: Role of glycated proteins in the detection and monitoring of diabetes in cynomolgus monkeys. Lab Anim Sci 43:72-77, 1993
19. Wagner JD, Bagdade JD, Litwak KN, et al: Increased glycation of plasma lipoproteins in diabetic cynomolgus monkeys. Lab Anim Sci 46:31-35, 1996
20. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 18:499-502, 1972
21. Edwards IJ, Rudel LL, Terry JG, et al: Caloric restriction in rhesus monkeys reduces low density lipoprotein interaction with arterial proteoglycans. J Gerontol 53A:B443-448, 1998
22. Salisbury BGJ, Wagner WD: Isolation and preliminary characterization of proteoglycans dissociatively extracted from human aorta. J Biol Chem 256:8050-8057, 1981
23. Chandrasekhar S, Esterman MA, Hoffman HA: Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal Biochem 161:103-108, 1987
24. Blumenkrantz N, Asboe-Hansen G: New method for the determination of uronic acids. Anal Biochem 54:484-489, 1973
25. Fager G, Camejo G, Olsson U, et al: Binding of platelet-derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human arterial smooth muscle cells. J Cell Physiol 163:380-392, 1995
26. Steele RH, Wagner WD, Rowe HA, et al: Artery wall derived proteoglycan-plasma lipoprotein interaction: Lipoprotein binding properties of extracted proteoglycans. Atherosclerosis 65:51-62, 1987
27. Manning JM, Gebre AK, Edwards IJ, et al: Dietary polyunsaturated fat decreases interaction between low density lipoproteins and arterial proteoglycans. Lipids 29:635-641, 1994
28. Edwards IJ, Gebre AK, Wagner WD, et al: Reduced proteoglycan binding of low density lipoproteins from monkeys (Macaca fascicularis) fed a fish oil verus lard diet. Arteriosler Thromb 11:1778-1785, 1991
29. Anber V, Griffin BA, McConnel M, et al: Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261-271, 1996
30. UK Prospective Diabetes Study Group 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
31. UK Prospective Diabetes Study Group 34: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854-865, 1998
32. Grant PJ: The effects of metformin on cardiovascular risk factors. Diabetes Metab Rev 11:S43-S50, 1995 (suppl 1)
33. Giugliano D, Quatraro A, Consoli G, et al: Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44:107-112, 1993
34. Niskanen L, Turpeinen A, Penttila I, et al: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in Type 2 diabetes. Diabetes Care 21:1861-1869, 1998
35. Hamsten A, Wallidus G, Szamosi A, et al: Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 73:1097-1110, 1986
36. Camejo G, Lopez A, Lopez P, et al: Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 55:93-105, 1985
37. Olsson U, Camejo G, Hurt-Camejo E, et al: Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor. Arterioscler Thromb Vasc Biol 17:149-155, 1997
38. Lyons TJ, Baynes JW, Patrick JS, et al: Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: Correlations with other parameters of glycaemic control. Diabetologica 29:685-689, 1986
39. Stewart JM, Kilpatrick ES, Cathcart S, et al: Low-density lipoprotein particle size in type 2 diabetic patients and age matched controls. Ann Clin Biochem 31:153-159, 1994
40. Cohen MP, Lautenslager G, Shea E: Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 31:707-713, 1993
41. Cutiss LK, Witztum JL: A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. J Clin Invest 72:1427-1438, 1983
42. Klein RL, Laimins M, Lopes-Virella MF: Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 44:1093-1098, 1995
43. Krämer-Guth A, Quaschning T, Galle J, et al: Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur J Clin Invest 27:460-468, 1997
44. Hurt-Camejo E, Camejo G, Rosengren B, et al: Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 31:1387-1398, 1990
45. Carmena R, Ascaso JF, Camejo G, et al: Effect of olive and sunflower oils on low density lipoprotein level, composition, size oxidation and interaction with arterial proteoglycans. Atherosclerosis 125:243-255, 1996
46. Wagner WD, Edwards IJ, St. Clair RW, et al: Low density lipoprotein interaction with artery derived proteoglycan: The influence of LDL particle size and the relationship to atherosclerosis susceptibility. Atherosclerosis 75:49-59, 1989